Literature DB >> 15294299

The toxicity of recombinant proteins in Escherichia coli: a comparison of overexpression in BL21(DE3), C41(DE3), and C43(DE3).

Laurence Dumon-Seignovert1, Guillaume Cariot, Laurent Vuillard.   

Abstract

Two mutant strains of Escherichia coli BL21(DE3), called C41(DE3) and C43(DE3) and originally described by Miroux and Walker, are frequently used to overcome the toxicity associated with overexpressing recombinant proteins using the bacteriophage T7 RNA polymerase expression system. Even when the toxicity of the plasmids is so high that it prevents transformation in the strain BL21(DE3), the toxic proteins can often be expressed successfully in C41(DE3) and/or C43(DE3). In this work, using a range of plasmids coding for several types of proteins, we investigated in BL21(DE3), C41(DE3), and C43(DE3) their ability to undergo transformation and to express. While transformation was always possible in C41(DE3) and C43(DE3), we could not obtain transformants in BL21(DE3) for 62% of the expression vectors tested. Moreover, after induction, the expression of heterologous proteins in both mutant strains is generally better than in BL21(DE3). In this study, we also enhanced the stability of plasmids in culture during the expression of proteins by adding the par locus from the plasmid pSC101 to the vector backbone. The stability of a subset of the plasmids (measured 3 h after induction) was determined in C41(DE3) and C43(DE3) and varies from 62 to 92% for C43(DE3) and from 10 to 90% for C41(DE3). This study demonstrates the usefulness of these strains C41(DE3) and C43(DE3) in solving the problem of plasmid instability during the expression of toxic recombinant proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294299     DOI: 10.1016/j.pep.2004.04.025

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  62 in total

1.  Optimization of Expression and Purification of Recombinant Archeoglobus fulgidus F420H2:NADP+ Oxidoreductase, an F420 Cofactor Dependent Enzyme.

Authors:  Cuong Quang Le; Ebenezer Joseph; Toan Nguyen; Kayunta Johnson-Winters
Journal:  Protein J       Date:  2015-12       Impact factor: 2.371

Review 2.  Adaptational properties and applications of cold-active lipases from psychrophilic bacteria.

Authors:  Jonathan Maiangwa; Mohd Shukuri Mohamad Ali; Abu Bakar Salleh; Raja Noor Zaliha Raja Abd Rahman; Fairolniza Mohd Shariff; Thean Chor Leow
Journal:  Extremophiles       Date:  2014-12-04       Impact factor: 2.395

3.  Structure Determination of Membrane Proteins Using X-Ray Crystallography.

Authors:  Evan Billings; Karl Lundquist; Claire Overly; Karthik Srinivasan; Nicholas Noinaj
Journal:  Methods Mol Biol       Date:  2021

4.  One step engineering of T7-expression strains for protein production: increasing the host-range of the T7-expression system.

Authors:  Yun Kang; Mike S Son; Tung T Hoang
Journal:  Protein Expr Purif       Date:  2007-07-12       Impact factor: 1.650

5.  Chondroitin Lyase from a Marine Arthrobacter sp. MAT3885 for the Production of Chondroitin Sulfate Disaccharides.

Authors:  Varsha Kale; Ólafur Friðjónsson; Jón Óskar Jónsson; Hörður G Kristinsson; Sesselja Ómarsdóttir; Guðmundur Ó Hreggviðsson
Journal:  Mar Biotechnol (NY)       Date:  2015-04-28       Impact factor: 3.619

6.  Construction of a synthetic protein using PCR with a high essential amino acid content for nutritional purposes.

Authors:  Ma I Sánchez-Crisóstomo; M I Rojo-López; A Sharma; J C Cancino-Diaz; H Jaimes-Díaz; J A Ariza-Ortega; E Madrigal-Santillán; G Betanzos-Cabrera
Journal:  Mol Biol Rep       Date:  2019-02-01       Impact factor: 2.316

7.  The Scottish Structural Proteomics Facility: targets, methods and outputs.

Authors:  Muse Oke; Lester G Carter; Kenneth A Johnson; Huanting Liu; Stephen A McMahon; Xuan Yan; Melina Kerou; Nadine D Weikart; Nadia Kadi; Md Arif Sheikh; Stefan Schmelz; Mark Dorward; Michal Zawadzki; Christopher Cozens; Helen Falconer; Helen Powers; Ian M Overton; C A Johannes van Niekerk; Xu Peng; Prakash Patel; Roger A Garrett; David Prangishvili; Catherine H Botting; Peter J Coote; David T F Dryden; Geoffrey J Barton; Ulrich Schwarz-Linek; Gregory L Challis; Garry L Taylor; Malcolm F White; James H Naismith
Journal:  J Struct Funct Genomics       Date:  2010-04-24

8.  Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics.

Authors:  Sacha J Pidot; Jessica L Porter; Laurent Marsollier; Annick Chauty; Florence Migot-Nabias; Cyril Badaut; Angèle Bénard; Marie-Therese Ruf; Torsten Seemann; Paul D R Johnson; John K Davies; Grant A Jenkin; Gerd Pluschke; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

9.  An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.

Authors:  José M Aguilar-Yáñez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio A García-Echauri; Felipe López-Pacheco; David Bulnes-Abundis; Johari Salgado-Gallegos; Itzel M Lara-Mayorga; Yenny Webb-Vargas; Felipe O León-Angel; Ramón E Rivero-Aranda; Yuriana Oropeza-Almazán; Guillermo M Ruiz-Palacios; Manuel I Zertuche-Guerra; Rebecca M DuBois; Stephen W White; Stacey Schultz-Cherry; Charles J Russell; Mario M Alvarez
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

10.  High-level production, solubilization and purification of synthetic human GPCR chemokine receptors CCR5, CCR3, CXCR4 and CX3CR1.

Authors:  Hui Ren; Daoyong Yu; Baosheng Ge; Brian Cook; Zhinan Xu; Shuguang Zhang
Journal:  PLoS One       Date:  2009-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.